Fig. 4 Soluble Cu (a) and As (b) after 0 (initial), 7, 14, and 21 days of (bio oxidative assays, in inoculated (experimental) and non-inoculated (control) trials (solid and dotted lines, respectively).
While promising results have been observed in clinical trials, solid success remains elusive since we lack understanding of the basic principles that govern the dynamical interactions between the virus and the cancer.
In Figure 2, we show performance for the congruent audiovisual trained group (green), incongruent audiovisual trained group (blue), and the unisensory trained group (red), for visual-only trials (solid lines) and audiovisual trials (dashed lines) across the five days of training.
(B ) Example VTA unit's average reward site responses for correct trials (solid line) and error trials (dashed line).
For units recorded on the SWM task, the average nosepoke triggered PETH for correct trials (solid blue lines) and for error trials (red dashed lines) are shown.
(A and B ) Example neuron cue-aligned firing rates for aborted (dashed lines) and non-aborted trials (solid lines) on R-present trials (left; R-contra, R-ipsi) and R-absent trials (right; P-contra, P-ipsi).
(E ) The Purkinje cell firing rate (baseline subtracted) during the first (dashed lines) and second trials (solid lines) of CF – No CF (blue) and No CF – No CF pairs (black) during VOR-decrease training.
(C ) The Purkinje cell firing rate (baseline subtracted) during the first (dashed lines) and second trials (solid lines) of CF No CF (red) and No CF No CF pairs (black) during VOR-increase training.
ATN-224 is a second-generation choline salt of TM with improved stability, which has been tested in two phase I clinical trials (solid tumours and haematological malignancies) (Berenson et al, 2006; Lowndes et al, 2006) and is currently being investigated in three phase II trials (melanoma, prostate and multiple myeloma).
